THE TIMES | The Tech Entrepreneur Working on a Reversible Male Contraceptive
In the middle of the last century, two remarkable women in their seventies drove the production of a contraceptive pill that revolutionised American society and underpinned the movement for women’s rights.
Now a young tech entrepreneur hopes to do something similar for men by offering what he bills as a cheap and reversible form of “male birth control”.
ORIGINALLY POSTED ON THE TIMES
MARCH 2024
In the middle of the last century, two remarkable women in their seventies drove the production of a contraceptive pill that revolutionised American society and underpinned the movement for women’s rights.
Now a young tech entrepreneur hopes to do something similar for men by offering what he bills as a cheap and reversible form of “male birth control”.
“Look inside here,” says Luke Fox, founder of Next Life Sciences, holding up a vial containing a treacly substance resembling pale golden syrup. “This is the hydrogel.”
It is designed to be injected into the vas deferens, the duct that carries sperm from the testicles during ejaculation. There it forms a filter that blocks anything bigger than one thousandth of a millimetre.
READ MORE ON THE TIMES
NPR | Male birth control is the 'holy grail' for one Flagstaff company
Nearly half of all pregnancies worldwide are unplanned. And despite the many birth control options for women in the U.S., 1 in 5 say they aren’t using their ideal method. A startup biotech company in Flagstaff says the answer is birth control for men. And they’re working to make that idea a reality.
ORIGINALLY POSTED ON NPR KNAU
MARCH 2024
Nearly half of all pregnancies worldwide are unplanned. And despite the many birth control options for women in the U.S., 1 in 5 say they aren’t using their ideal method. A startup biotech company in Flagstaff says the answer is birth control for men. And they’re working to make that idea a reality.
READ MORE ON NPR KNAU
Male Contraceptive Initiative Supports the Launch of Plan A™ Male Birth Control
NEXT Life Sciences is announcing its partnership with Male Contraceptive Initiative, the largest 501(c)(3) non-profit in the world dedicated to advancing male contraception. This partnership includes a grant of $400K to NEXT to support clinical trial research toward Plan A™, being developed as a long-acting, non-hormonal, reversible contraceptive method.
ORIGINALLY POSTED ON AP News
FEBRUARY 2024
MCI grants $400K to support NEXT’s clinical trial research.
LOS ANGELES, CALIFORNIA – NEXT Life Sciences, Inc. (NEXT) is announcing its partnership with Male Contraceptive Initiative (MCI), the largest 501(c)(3) non-profit in the world dedicated to advancing male contraception. This partnership includes a grant of $400K to NEXT to support clinical trial research toward Plan A™, being developed as a long-acting, non-hormonal, reversible contraceptive method. This grant follows a successful fundraising round led by Bolt.com founder Ryan Breslow and The Family, with participation from Transform VC and a combination of angel investors and early-stage venture funds.
“We’re thrilled and extremely grateful to MCI for their commitment to excellence and innovation in the male contraceptive space,” said NEXT Life Sciences Founder and CEO L.R. Fox. “NEXT is dedicated to developing a contraceptive solution that will finally meet men’s need for long-term effectiveness, convenient reversibility, and ease of access. We want to improve the quality of life for men and couples by giving men equitable access to participate in family planning with an option like Plan A™. This investment from MCI will help accelerate our progress towards those goals.”
“NEXT Life Sciences represents an exciting partnership opportunity. They have been integral at advancing the non-hormonal male contraceptive field in an effort to provide reproductive equity to all people, and particularly men who, despite all the incredible efforts to date, still only have two methods of birth control: condoms and vasectomy,” said MCI Executive Director Heather Vahdat, MPH. “The number of men and their partners expressing the desire for male contraceptive options continues to increase, and part of MCI’s dedication to accelerating product development includes thinking proactively about how to ensure a variety of delivery options. We are pleased to be able to get behind the talent and energy of NEXT Life Sciences in order to achieve a real vision for a shared contraceptive future.”
“We have been excited about the progress of the Plan A™ technology since 2019, when we provided an initial grant to advance the work of Vasalgel®, the hydrogel in Plan A™. Given the success of their science to date, we are pleased to expand our collaboration as NEXT Life Sciences represents an exciting device-based, non-hormonal male contraceptive method.” continued MCI Chief Research Officer Logan Nickels, PhD. “It is critically important that we develop, in parallel, a robust and diverse mix of contraceptive products for men in order to ensure that individual’s unique needs and interests are meaningfully addressed by the next generation of male contraception. NEXT Life Sciences and their product Plan A™ represent an exciting opportunity to do just this by providing a device-based, long-acting, and reversible contraceptive for male users.”
“Plan A™ will be a great addition to the family planning options involving men and couples looking to prevent pregnancy,” said Dr. Aaron Tabor, Chief Technology Officer, NEXT Life Sciences. “With the advances we’ve made in testing and confirming the long-term durability of Plan A™, we’re thrilled to have this support from MCI to bring this technology to the world.”
“The landscape for contraception is rapidly changing, and as more men get involved in family planning, they need more options,” said Dr. Robert Kellar, Chief Science Officer at NEXT Life Sciences. “Our team at NEXT Life Sciences is extremely excited to get started on the funded work which is designed to help accelerate our technology to commercialization.”
Plan A™ is being developed by NEXT Life Sciences as a male contraceptive that would be administered during a quick outpatient procedure in which a biocompatible hydrogel, Vasalgel®, is placed within the vas deferens (the tubes that carry sperm), creating a flexible filter that prevents the flow of sperm. Plan A™ is designed to create up to 10 years of pregnancy prevention with the allowance for reversibility at any time through a second procedure to dissolve the gel.
Following the acquisition of the worldwide license to Vasalgel® in 2022 from the Parsemus Foundation, NEXT Life Sciences has pushed the technology forward, optimizing it into Plan A™, to bring it through FDA marketing authorization and finally to market. Backed by renowned clinicians and researchers within the contraceptive and hydrogel communities, the company has plans to start clinical trials for Plan A™ in 2024, followed by submission to the FDA for marketing authorization.
About NEXT Life Sciences: NEXT Life Sciences, Inc. (NEXT) is a medical device company striving to transform lives through the development of its lead program, Plan A™, designed to provide a non-hormonal, long-lasting, and reversible contraceptive solution for men. NEXT’s executive management team and board members have a proven track record of leadership across early-stage research, product development, and global commercialization, having served in leadership roles at successful medical device and contraceptive companies that developed and launched products that achieved iconic status. For more information, visit www.nextlifesciences.org and www.planaformen.com.
About Male Contraceptive Initiative: Male Contraceptive Initiative’s vision is “Reproduction Autonomy for All”, and works to accomplish this by bringing new male contraceptives to market. The non-profit accomplishes this through direct funding, technical support, research, and advocacy. They believe that couples deserve options and that they offer the biggest potential impact by focusing on male contraceptives. It’s time men are given more opportunities to contribute toward family planning. Please visit their website for more information: www.malecontraceptive.org.
READ THE ORIGINAL ARTICLE ON AP News
The 'IUD' for men: Could Plan A be the future of male contraception?
Being dubbed the ‘IUD’ for men (coil if you’re a Brit), Plan A™ is aiming to bring the first non-hormonal, long-lasting and reversible male contraception to the market. If you’re someone who’s struggled with the female birth control options, then this may be music to your ears. You may also have questions.
We spoke to L.R. Fox, the CEO and Founder of Next Life Sciences (the company behind Plan A™) about all things male birth control.
ORIGINALLY POSTED ON The News Movement
FEBRUARY 2024
Being dubbed the ‘IUD’ for men (coil if you’re a Brit), Plan A™ is aiming to bring the first non-hormonal, long-lasting and reversible male contraception to the market. If you’re someone who’s struggled with the female birth control options, then this may be music to your ears. You may also have questions.
We spoke to L.R. Fox, the CEO and Founder of Next Life Sciences (the company behind Plan A™) about all things male birth control. We asked him some of the big questions - How does it work? Will men take it? Is there an appetite for it? What does this mean for women’s birth control options? Will there be side effects?
Watch our chat with Fox to find out everything you want to know, from one of the people trying to reach a new frontier in reproductive health.
WATCH MORE ON The News Movement
NEXT Life Sciences Announces Successful Clinical Evaluation of the Delivery Method for Plan A™ Contraception for Men
NEXT Life Sciences has most recently concluded a successful clinical evaluation of its new proprietary delivery method. Based on the results of this evaluation, it is expected that Plan A™ Contraception’s novel delivery method will be easier than historical intraluminal vas deferens delivery methods.
ORIGINALLY POSTED ON AP News
FEBRUARY 2024
Novel method represents an evolution for male contraceptive research.
LOS ANGELES, CALIFORNIA, UNITED STATES, February 12, 2024 /EINPresswire.com/ -- NEXT Life Sciences, the company designing a non-hormonal, long-lasting, and reversible male birth control known as Plan A™, has most recently concluded a successful clinical evaluation of its new proprietary delivery method. Based on the results of this evaluation, it is expected that Plan A™ Contraception’s novel delivery method will be easier than historical intraluminal vas deferens delivery methods. Using this method, there was a positive confirmation of successful intraluminal access to the vas lumen (the tube that carries sperm) in 23/24 (96%) vas deferens, compared with only 16/24 (67%) vas deferens accessed using traditional methods that deploy larger devices and needle-based access devices.
The entire Plan A™ design in development will include a non-hormonal, reversible hydrogel solution, called Vasalgel®, which is inserted into the vas deferens to block the flow of sperm. The new proprietary delivery method was evaluated by Michel Labrecque, MD PhD, a member of NEXT’s Medical Advisory Board, and globally-renowned medical doctor, professor, clinical researcher, and pioneer in the field of no-scalpel vasectomies.
Dr. Labrecque conducted the clinical evaluation of this novel Plan A™ delivery method among 24 male volunteers at two Vasectomie Québec clinical sites in Quebec City. Dr. Labrecque has performed over 40,000 vasectomies and is an expert in the research and background of male contraceptive methods, including a previous iteration of the Vasalgel® hydrogel technology in India, known as RISUG. NEXT Life Sciences with Dr. Labrecque is developing this minimally invasive procedure in order to allow a provider to confirm with greater accuracy that the Vasalgel® is properly positioned within the vas deferens to act as a contraceptive.
After a safe and successful completion of the evaluation, Dr. Labrecque concluded, “The delivery method with the Plan A™ system is designed to be significantly safer than previous vas lumen access and hydrogel delivery methods.” He continued, “In both the formulation of its hydrogel and its unique delivery method, Plan A™ represents the evolution of a long line of research and advances in male contraceptive research.”
“Plan A™ expands upon decades of research and clinical experience with hydrogel-based contraception,” explained L.R. Fox, CEO of NEXT Life Sciences. “We’re pioneering a new delivery method because we want providers to have ease and comfort when providing Plan A™ to patients—which will be necessary to make this technology available at scale once it is approved.”
Today’s announcement of a successful clinical evaluation of Plan A™ Contraception’s delivery method in 24 men comes shortly after NEXT Life Sciences’ announcement of the conclusion of an oversubscribed successful funding round and its plans to initiate clinical trials of the Plan A™ system in its entirety (both the hydrogel and the delivery method) in 2024.
About NEXT Life Sciences: NEXT Life Sciences, Inc. (NEXT) is a medical device company striving to transform lives through the development of its lead program, Plan A™, designed to provide a non-hormonal, long-lasting, and reversible contraceptive solution for men. NEXT’s executive management team and board members have a proven track record of leadership across early-stage research, product development, and global commercialization, having served in leadership roles at successful medical device and contraceptive companies that developed and launched products that achieved iconic status. For more information, visit https://www.nextlifesciences.org/ and https://www.planaformen.com/.
READ THE ORIGINAL ARTICLE ON AP News
Saturday Night Live: Weekend Update Covers New Male Contraceptive Plan A™
In January, Saturday Night Live’s Weekend Update covered Plan A™ and touched on the perception of male involvement with contraceptives. The truth is that men do generally want to be and already are actively trying to participate in family planning more.
ORIGINALLY POSTED ON Weekend Update
JANUARY 2024
Saturday Night Live’s Weekend Update covered Plan A™ and touched on the perception of male involvement with contraceptives. The truth is that men do generally want to be and already are actively trying to participate in family planning more.
WATCH MORE ON Weekend Update
StartUp Health Insights: NEXT Life Sciences Secures $2.5M for ‘Plan A’ Male Birth Control
“With Plan A™, our goal is to change lives by giving men the ability to participate equally in family planning, so that couples have a more equitable relationship and the tools needed to be intentional about their futures,” said Health Transformer L.R. Fox, CEO & Founder of NEXT Life Sciences.
ORIGINALLY POSTED ON StartUp Health
JANUARY 2024
NEXT Life Sciences Secures $2.5M - The round, which brought total seed funding to date to $4M, was led by Ryan Breslow’s The Family, with participation from StartUp Health, Transform VC, Brock Pierce, Pay It Forward Venture Capital, Particular Ventures, Keno Peer, Unpopular Ventures, and Joy Fund.
READ THE ORIGINAL ARTICLE ON StartUp Health
Male birth control maker raises $2.5 million to develop “Plan A”
Next Life Sciences has raised $2.5 million to develop a male contraceptive product called Plan A, which could become a nonsurgical alternative to vasectomies.
ORIGINALLY POSTED ON Axios
JANUARY 2024
Next Life Sciences has raised $2.5 million to develop a male contraceptive product called Plan A, which could become a nonsurgical alternative to vasectomies.
Why it matters: This could help balance family-planning responsibilities that fall disproportionately on women.
Zoom in: Plan A is being pitched as a medical device instead of as a drug, which Next Life Sciences CEO L.R. Fox says should reduce the time and expense of clinical trials that begin later this year.
READ THE ORIGINAL ARTICLE ON Axios
Male contraceptive under development blocks sperm with quick injection, easily reversible
Vasectomies and condoms have traditionally been the only ways men can use contraception, but a Los Angeles-based health startup wants to change that.
ORIGINALLY POSTED ON New York Post
JANUARY 2024
Vasectomies and condoms have traditionally been the only ways men can use contraception, but a Los Angeles-based health startup wants to change that.
NEXT Life Sciences is pioneering Plan A, a procedure in which men pay a 10-minute visit to a doctor to receive an injection of a hydrogel into the vas deferens — the 30-centimeter tube that transports sperm.
Once injected, the hydrogel morphs into a semi-solid, thick, and sticky substance that filters sperm out of semen during ejaculation — maintaining its efficacy for 10 years, according to the company.
“It’s all of the juice and none of the seed,” L.R. Fox, the 29-year-old founder and CEO of NEXT Life Sciences, told The Post.
READ THE ORIGINAL ARTICLE ON New York Post
The Dude Pill. Plan A’s male birth control.
NextLife just raised VC money to launch Plan A - a new birth control… for men — We think there’s just as much innovation in the name…
ORIGINALLY POSTED ON The Best One Yet
JANUARY 2024
NEXT Life just raised VC money to launch Plan A - a new birth control… for men.
LISTEN ON The Best One Yet
The Family Leads NEXT Life Sciences $2.5 Million Funding Round for Plan A Male Birth Control
Ryan Breslow joins as a Strategic Advisor to bring male birth control to market.
ORIGINALLY POSTED ON Associated Press
JANUARY 2024
LOS ANGELES—NEXT Life Sciences, the maker of the male contraceptive product Plan A™, announced today that it has secured an oversubscribed $2.5M round of funding to help advance its mission of bringing Plan A™ to market. The Family, a high-impact startup accelerator led the round with participation from Transform VC and a combination of angel investors and early-stage Venture funds including entrepreneur Brock Pierce, Transform VC, StartupHealth, Pay It Forward Venture Capital, Particular Ventures, Keno Peer, Unpopular Ventures, and Joy Fund, bringing total seed funding to date to $4M.
The Family’s founder Ryan Breslow who is known for building the multi-billion-dollar company Bolt and his newest venture Love.com, will join NEXT Life Sciences as a strategic advisor and provide insights needed to bring Plan A™ to market.
“My mission for Family is to back top founders working on truly world-changing products and bring them to market more quickly,” said The Family Founder Ryan Breslow. “Plan A™ is unleashing bodily autonomy; it’s giving men the ability to share responsibility over long-term contraceptive decisions. I’m all-in.”
“We couldn’t be more thrilled that the Family recognizes the potential impact for Plan A™ and we’re honored to welcome Ryan as a strategic advisor to help guide our team as we work to bring a revolutionary contraception to the market,” said NEXT Life Sciences, Inc. Founder and CEO L. R. Fox. “With Plan A™, our goal is to change lives by giving men the ability to participate equally in family planning, so that couples have a more equitable relationship and the tools needed to be intentional about their futures.”
NEXT is developing Plan A™ to be a non-hormonal, long-acting, and reversible on-demand, contraceptive for men. The design of Plan A utilizes a hydrogel that acts as a flexible filter to block the flow of sperm within the male vas deferens, preventing pregnancy. The hydrogel used within Plan A™ is commonly known as Vasalgel®, a technology that earned significant attention during its 10 years of development with the non-profit Parsemus Foundation and shows a promising track record of success from pre-clinical data. The exclusive worldwide license for Vasalgel® was acquired by NEXT in 2022, with the goal to bring this technology through FDA authorization and finally to market.
NEXT plans to start clinical trials for Plan A™ in 2024, followed by submission to the FDA.
About NEXT Life Sciences
NEXT Life Sciences, Inc. (NEXT) is a medical device company striving to transform lives through the development of its lead program, Plan A™, designed to provide a non-hormonal, long-lasting, and reversible contraceptive solution for men. NEXT’s executive management team and board members have a proven track record of leadership across early-stage research, product development, and global commercialization, having served in leadership roles at successful medical device and contraceptive companies that developed and launched products that achieved iconic status. For more information, visit https://www.nextlifesciences.org/ and https://www.planaformen.com/.
Disclaimer
All forward-looking statements are not guarantees of future performance and undue reliance should not be placed on them. Statements within this document have not been evaluated by the Food and Drug Administration. Plan A™ is currently not approved by FDA for commercial distribution.
READ THE ORIGINAL ARTICLE ON Associated Press
Bolt’s Ryan Breslow Is Backing This Male Birth Control Startup
The startup just raised a $2.5 million seed round led by Bolt cofounder Ryan Breslow's VC firm. NEXT wants to start clinical trials this year, and says its birth control could be ready by 2026.
ORIGINALLY POSTED ON Business Insider
JANUARY 2024
The market for male birth control is growing. One startup is touting a nonhormonal, long-lasting option — and thinks the tech could be ready for use in two years.
NEXT Life Sciences is taking a new approach with its male contraceptive called Plan A. The product uses Vasalgel, a hydrogel that blocks the flow of sperm through the vas deferens to prevent pregnancy.
This month, the startup landed fresh funding to power Plan A's first clinical trials, raising $2.5 million in seed funding led by Ryan Breslow's venture fund The Family, Business Insider has learned exclusively. Breslow, the founder of fintech startup Bolt, will now serve as a strategic advisor to NEXT.
NEXT's oversubscribed seed round included funding from entrepreneur Brock Pierce, Transform VC, StartupHealth, Pay It Forward Venture Capital, Particular Ventures, Keno Peer, Unpopular Ventures, and Joy Fund. The startup had raised $1.5 million in pre-seed funding in June.
READ MORE ON Business Insider
Paving the Way for Male Birth Control
L.R. is a serial entrepreneur founding a number of different companies both in the aerospace and life science industries. L.R. most recently founded WhiteFox Defense Technologies, a leading provider of cutting-edge counter-drone solutions, and NEXT Life Sciences. Since this was recorded live at HLTH 2023 we only discussed NEXT Life Sciences in this episode. They are currently developing Plan A, which is reversible male birth control. Enjoy the show!
ORIGINALLY POSTED ON Medi-Ops
DECEMBER 2023
L.R. is a serial entrepreneur founding a number of different companies both in the aerospace and life science industries. L.R. most recently founded WhiteFox Defense Technologies, a leading provider of cutting-edge counter-drone solutions, and NEXT Life Sciences. Since this was recorded live at HLTH 2023 we only discussed NEXT Life Sciences in this episode. They are currently developing Plan A, which is reversible male birth control. Enjoy the show!
READ MORE ON Medi-Ops
What Should The Future Look Like?
LR Fox CEO and Founder of Next Life Sciences is with us. Fox is a high-energy serial entrepreneur who brings us incredible insights. We get into what the future should look like. Also, why you as a Med Tech Entrepreneur should embrace the regulatory environment, it can work towards your advantage.
ORIGINALLY POSTED ON Med Tech Gurus
DECEMBER 2023
LR Fox CEO and Founder of Next Life Sciences is with us. Fox is a high energy seral entrepreneur who brings us incredible insights.
We get into what the future should look like. Also, why you as a Med Tech Entrepreneur should embrace the regulatory environment, it can work towards your advantage.
READ MORE ON Med Tech Gurus
New Horizons in Birth Control for Men
“This year, while we continue to change the global stigma around vasectomies, I’d like to challenge us to also look further out and envision a world where men regularly and actively participate in family planning.” - L.R. Fox
ORIGINALLY POSTED ON Femtech Insider
NOVEMBER 2023
Every November, we join in celebrating World Vasectomy Day to raise awareness about what is currently the only form of long-acting contraception designed specifically for men: vasectomies. This year, while we continue to change the global stigma around vasectomies, I’d like to challenge us to also look further out and envision a world where men regularly and actively participate in family planning. This world would not only require better access to traditional vasectomies but also access to some of the easily reversible, long-acting male birth control options that are on the horizon.
READ MORE ON Femtech Insider
This World Vasectomy Day, Let’s Look to Vasectomies and Beyond
The data seems to be clear: getting men more involved in their reproductive health care only stands to help men, women, and families in the long term – and men are currently taking a momentous interest in their reproductive health.
- Dominick Shattuck, PhD
ORIGINALLY POSTED ON The Good Men Project
NOVEMBER 2023
November 17 marks World Vasectomy Day, and in the time since the U.S. Supreme Court decided Dobbs v. Jackson Women’s Health Organization, overturning the nationwide right to abortion, there has been an interesting uptick in men seeking out reproductive health care, specifically vasectomies.
READ MORE ON The Good Men Project
Reimagining Male Contraception
How would the world look like if men had the most efficient and reversible means of birth control? The outstanding work that L.R. Fox and his team at NEXT Life Sciences are leading might bring a very tangible answer to this question.
ORIGINALLY POSTED ON Impulse
OCTOBER 2023
How would the world look like if men had the most efficient and reversible means of birth control?
The outstanding work that L.R. Fox and his team at NEXT Life Sciences are leading might bring a very tangible answer to this question.
Based on the pioneering work from Prof. Sujoy K. Guha and The Parsemus Foundation, they are developing one of the most promising male birth control methods medicine has ever known, under the name of Plan A.
As an American citizen who has grown under the Foster Care program, Fox (as he likes to be called) has witnessed firsthand the dramatic consequences that unplanned pregnancies can have on individuals and their relatives in the long term.
According to him, we have gone quite far already in terms of available options for women and men when it comes to birth control methods.
But Plan A could be a revolution in the space, as it is completely hormone-free, painless to deliver and revert, and has an efficacy duration that is way beyond current standards.
And most importantly, it can redistribute the heavy responsibility of family planning from women to men.
In this episode, we talk about the science behind Plan A, where the technology comes from, how far is it from being available worldwide, and what it would change for society as a whole!
A fascinating conversation with a visionary founder, deeply led by the purpose of fostering a positive impact in the world, and with a strong social approach to entrepreneurship!
READ MORE ON Impulse
A Birth Control Revolution: New Options for Men on the Horizon
As many men become increasingly engaged in family planning, a new era of male contraceptives arrives.
ORIGINALLY POSTED ON US News & World Report
OCTOBER 2023
Last month, we celebrated World Contraception Day, and this year, we have a lot to cheer: Women’s contraceptive use has increased worldwide, including in the U.S., where the FDA recently approved the first over-the-counter female birth control pill. As we head into the next era for birth control access, I want to challenge us to think even bigger: What would it look like if men had practical options to share in the responsibility of family planning?
READ MORE ON US News & World Report
Mission-Driven Entrepreneurship with Founder L.R. Fox
When it comes to contraception, the burden has historically fallen on women. However, thanks to L.R. Fox (aka Fox) and his team at NEXT Life Sciences, a paradigm shift is gradually taking root.
ORIGINALLY POSTED ON Medsider
SEPTEMBER 2023
When it comes to contraception, the burden has historically fallen on women. However, thanks to L.R. Fox (aka Fox) and his team at NEXT Life Sciences, a paradigm shift is gradually taking root.
Fox isn’t your average entrepreneur. While many leave footprints in one or two different fields, his resume spans a wide range of tightly regulated industries, including cybersecurity, defense, and aerospace. On top of that, he was featured in Forbes' list of 30 under 30 in 2019 and founded WhiteFox Defense Technologies, a trailblazer in drone airspace security. Most recently, he dove into the world of medtech head-first, and the prospects are no less promising than in any of his previous ventures.
READ MORE ON Medsider
Plan A™ Offers a New Option in Male Birth Control
Founder and CEO L.R. Fox discusses what happens when people aren’t able to choose if/when to have a child and how he founded NEXT Life Sciences and Plan A to increase access to family planning.
ORIGINALLY POSTED ON Medical Device + Diagnostic Industry
Katie Hobbins | Aug 22, 2023
Recently, MD+DI sat down with L.R. Fox, founder and CEO of NEXT Life Sciences, to discuss Plan A, a non-hormonal, long lasting, and reversible male contraception option that uses Vasalgel as a medical device to block the flow of sperm within the vas deferens for up to 10 years to prevent pregnancy. Highlighting the burden of birth control usually placed on women, Fox noted that Plan A would give men an option other than condoms or a vasectomy to play an active role in birth control and family planning.